Allele-Selective Inhibition of Mutant Huntingtin with 2-Thio- and C5- Triazolylphenyl-Deoxythymidine-Modified Antisense Oligonucleotides

Nucleic Acid Therapeutics

Volumn 25, Issue 5, 2015, Pages 266-274

  Østergaard, Michael E ^a   Kumar, Pawan ^b   Nichols, Josh ^a   Watt, Andrew ^a   Sharma, Pawan K ^c   Nielsen, Poul ^b   Seth, Punit P ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c KURUKSHETRA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 THIO DEOXYTHYMIDINE; ANTISENSE OLIGONUCLEOTIDE; C5 TRIAZOLYLPHENYL DEOXYTHYMIDINE; HETERODUPLEX; HUNTINGTIN; MUTANT PROTEIN; RIBONUCLEASE H; UNCLASSIFIED DRUG; HTT PROTEIN, HUMAN; NERVE PROTEIN; REPETITIVE DNA; RIBONUCLEASE HI; THYMIDINE;

ALLELE; ARTICLE; BIOCHEMICAL ANALYSIS; CHEMICAL MODIFICATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME DENATURATION; HETERODUPLEX ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; BASE PAIRING; GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RNA CLEAVAGE;

ALLELES; BASE PAIRING; BASE SEQUENCE; DNA REPEAT EXPANSION; HUMANS; MUTANT PROTEINS; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H; RNA CLEAVAGE; THYMIDINE;

EID: 84941894875     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2015.0547     Document Type: Article

References (40)

1. MacDonald ME, CM Ambrose, MP Duyao, RH Myers, C Lin, L Srinidhi, G Barnes, SA Taylor, M James, et al. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
2. Nasir J, SB Floresco, JR O'Kusky, VM Diewert, JM Richman, J Zeisler, A Borowski, JD Marth, AG Phillips and MR Hayden. (1995). Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811-823.
3. Walker FO. (2007). Huntington's disease. Lancet 369: 218-228.
4. Zuccato C, M Valenza and E Cattaneo. (2010). Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90:905-981.
5. Southwell AL, NH Skotte, CF Bennett and MR Hayden. (2012). Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med 18:634-643.
6. Carroll JB, SC Warby, AL Southwell, CN Doty, S Greenlee, N Skotte, G Hung, CF Bennett, SM Freier and MR Hayden. (2011). Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 19:2178-2185.
7. Eckstein F. (2014). Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24:374-387.
8. Seth PP, A Siwkowski, CR Allerson, G Vasquez, S Lee, TP Prakash, EV Wancewicz, D Witchell and EE Swayze. (2009). Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52:10-13.
9. Wu H, WF Lima, H Zhang, A Fan, H Sun and ST Crooke. (2004). Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 279:17181-17189.
10. Lima WF, H Wu and ST Crooke. (2001). Human RNases H. Methods Enzymol 341:430-440.
11. Cerritelli SM and RJ Crouch. (2009). Ribonuclease H: the enzymes in eukaryotes. FEBS J 276:1494-1505.
12. Ostergaard ME, AL Southwell, H Kordasiewicz, AT Watt, NH Skotte, CN Doty, K Vaid, EB Villanueva, EE Swayze, et al. (2013). Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41:9634-9650.
13. Seth PP, G Vasquez, CA Allerson, A Berdeja, H Gaus, GA Kinberger, TP Prakash, MT Migawa, B Bhat and EE Swayze. (2010). Synthesis and biophysical evaluation of 2′,4′-constrained 2′O-methoxyethyl and 2′,4′-constrained 2′O-ethyl nucleic acid analogues. J Org Chem 75:1569-1581.
14. Teplova M, G Minasov, V Tereshko, GB Inamati, PD Cook, M Manoharan and M Egli. (1999). Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA. Nat Struct Biol 6:535-539.
15. Seth PP and EE Swayze. (2014). Unnatural nucleoside analogs for antisense therapy. In: Natural Products in Medicinal Chemistry. Hanessian, S, ed. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, pp 403-440.
16. Herdewijn P. (2000). Heterocyclic modifications of oligonucleotides and antisense technology. Antisense Nucleic Acid Drug Dev 10:297-310.
17. Krieg AM. (2002). CPG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760.
18. Wagner RW, MD Matteucci, JG Lewis, AJ Gutierrez, C Moulds and BC Froehler. (1993). Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260:1510-1513.
19. Kumar P, B Baral, BA Anderson, DC Guenther, ME Ostergaard, PK Sharma and PJ Hrdlicka. (2014). C5-alkynylfunctionalized alpha-L-LNA: synthesis, thermal denaturation experiments and enzymatic stability. J Org Chem 79:5062-5073.
20. Kaura M, P Kumar and PJ Hrdlicka. (2014). Synthesis, hybridization characteristics, and fluorescence properties of oligonucleotides modified with nucleobase-functionalized locked nucleic acid adenosine and cytidine monomers. J Org Chem 79:6256-6268.
21. Kaura M, DC Guenther and PJ Hrdlicka. (2014). Carbohydrate-functionalized locked nucleic acids: oligonucleotides with extraordinary binding affinity, target specificity, and enzymatic stability. Org Lett 16:3308-3311.
22. Guenther DC, P Kumar, BA Anderson and PJ Hrdlicka. (2014). C5-amino acid functionalized LNA: positively poised for antisense applications. Chem Commun (Camb) 50:9007-9009.
23. Gutierrez AJ, TJ Terhorst, MD Matteucci and BC Froehler. (1994). 5-Heteroaryl-2′-deoxyuridine analogs. Synthesis and incorporation into high-affinity oligonucleotides. J Am Chem Soc 116:5540-5544.
24. Kumar P, M Hornum, LJ Nielsen, G Enderlin, NK Andersen, C Len, G Herve, G Sartori and P Nielsen. (2014). High-affinity RNA targeting by oligonucleotides displaying aromatic stacking and amino groups in the major groove. Comparison of triazoles and phenyl substituents. J Org Chem 79:2854-2863.
25. Andersen NK, H Dossing, F Jensen, B Vester and P Nielsen. (2011). Duplex and triplex formation of mixed pyrimidine oligonucleotides with stacking of phenyl-triazole moieties in the major groove. J Org Chem 76:6177-6187.
26. Kumar P, N Chandak, P Nielsen and PK Sharma. (2012). Sulfonamide bearing oligonucleotides: simple synthesis and efficient RNA recognition. Bioorg Med Chem 20:3843-3849.
27. Nowotny M, SA Gaidamakov, R Ghirlando, SM Cerritelli, RJ Crouch and W Yang. (2007). Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol Cell 28:264-276.
28. Kumar RK and DR Davis. (1997). Synthesis and studies on the effect of 2-thiouridine and 4-thiouridine on sugar conformation and RNA duplex stability. Nucleic Acids Res 25:1272-1280.
29. Nowotny M, SA Gaidamakov, RJ Crouch and W Yang. (2005). Crystal structures of RNase H bound to an RNA/ DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121:1005-1016.
30. Lima WF, JB Rose, JG Nichols, H Wu, MT Migawa, TK Wyrzykiewicz, G Vasquez, EE Swayze and ST Crooke. (2007). The positional influence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis. Mol Pharmacol 71:73-82.
31. Nowotny M, SM Cerritelli, R Ghirlando, SA Gaidamakov, RJ Crouch and W Yang. (2008). Specific recognition of RNA/DNA hybrid and enhancement of human RNase H1 activity by HBD. EMBO J 27:1172-1181.
32. Kordasiewicz HB, LM Stanek, EV Wancewicz, C Mazur, MM McAlonis, KA Pytel, JW Artates, A Weiss, SH Cheng, et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74:1031-1044.
33. DiFiglia M, M Sena-Esteves, K Chase, E Sapp, E Pfister, M Sass, J Yoder, P Reeves, RK Pandey, et al. (2007). Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 104:17204-17209.
34. Hu J, M Matsui, KT Gagnon, JC Schwartz, S Gabillet, K Arar, J Wu, I Bezprozvanny and DR Corey. (2009). Allelespecific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 27:478-484.
35. Pfister EL, L Kennington, J Straubhaar, S Wagh, W Liu, M DiFiglia, B Landwehrmeyer, J-P Vonsattel, PD Zamore and N Aronin. (2009). Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 19:774-778.
36. Southwell AL, NH Skotte, HB Kordasiewicz, ME Ostergaard, AT Watt, JB Carroll, CN Doty, EB Villanueva, E Petoukhov, et al. (2014). In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther 22:2093-2106.
37. Skotte NH, AL Southwell, ME Ostergaard, JB Carroll, SC Warby, CN Doty, E Petoukhov, K Vaid, H Kordasiewicz, et al. (2014). Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One 9:e107434.
38. Lima WF, JG Nichols, H Wu, TP Prakash, MT Migawa, TK Wyrzykiewicz, B Bhat and ST Crooke. (2004). Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J Biol Chem 279:36317-36326.
39. Ostergaard ME, B Gerland, JM Escudier, EE Swayze and PP Seth. (2014). Differential effects on allele selective silencing of mutant huntingtin by two stereoisomers of alpha,betaconstrained nucleic acid. ACS Chem Biol 9:1975-1979.
40. Ostergaard ME, G Thomas, E Koller, AL Southwell, MR Hayden and PP Seth. (2015). Biophysical and biological characterization of hairpin and molecular beacon RNase H active antisense oligonucleotides. ACS Chem Biol 10: 1227-1233.